Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Peptron Eyes Differentiation As Exenatide Progresses For Parkinson’s

Executive Summary

With the recent completion of GMP manufacturing facilities and sizable funding, South Korean peptide therapeutics company Peptron is set to begin a Phase II clinical trial of sustained release exenatide for Parkinsons, which if successful could pave the way to a first-in-class, disease-modifying treatment for the disease.

You may also be interested in...



Korea Regulatory Streamlining Plans Eye Innovation, Commercialization Support

South Korea's drug ministry, together with consumer and business groups, announces a raft of major regulatory innovation tasks it aims to achieve over the next few years, a major goal being to speed up patient access to innovation.

Asia Deal Watch: Hansoh, TiumBio Join Forces On Endometriosis Drug In Greater China

Plus deals involving Shionogi/ Grünenthal, CR Biopharma/ImmVira, Elevation Oncology/CSPC, Everest Medicines/TTY Biopharm and Dr. Reddy’s/Slayback

Korean Biopharma Today And Tomorrow: M&A, Investment, Governance

Experts shared views at a recent conference in Seoul on how the Korean biopharma industry has evolved and what needs to be done to move forward in the next 10 years. Policy efficiency and family ownership in the sector came in for particular scrutiny, with some calling for sweeping changes. 

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC123086

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel